CompletedPhase 3NCT03473613
Cabergoline Versus Calcium Infusion in Ovarian Hyperstimulation Syndrome Prevention
Studying Ovarian hyperstimulation syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Benha University
- Principal Investigator
- Ashraf N Elmantwe, MDBenha University
- Intervention
- Oral Cabergoline(drug)
- Enrollment
- 230 target
- Eligibility
- 18-45 years · FEMALE
- Timeline
- 2014 – 2017
Study locations (1)
- Ashraf nassif Elmantwe, Cairo, Elqalopia, Egypt
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03473613 on ClinicalTrials.govOther trials for Ovarian hyperstimulation syndrome
Additional recruiting or active studies for the same condition.